Literature DB >> 19915170

The use of baseline covariates in crossover studies.

Michael G Kenward1, James H Roger.   

Abstract

It is our experience that in many settings, crossover trials that have within-period baseline measurements are analyzed wrongly. A "conventional" analysis of covariance in this setting uses each baseline as a covariate for the following outcome variable in the same period but not for any other outcome. If used with random subject effects such an analysis leads to biased treatment comparisons; this is an example of cross-level bias. Using a postulated covariance structure that reflects the symmetry of the crossover setting, we quantify such bias and, at the same time, investigate potential gains and losses in efficiency through the use of the baselines. We then describe alternative methods of analysis that avoid the cross-level bias. The development is illustrated throughout with 2 example trials, one balanced and orthogonal and one highly unbalanced and nonorthogonal.

Mesh:

Substances:

Year:  2009        PMID: 19915170     DOI: 10.1093/biostatistics/kxp046

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  29 in total

1.  Morning exercise mitigates the impact of prolonged sitting on cerebral blood flow in older adults.

Authors:  Michael J Wheeler; David W Dunstan; Brianne Smith; Kurt J Smith; Anna Scheer; Jaye Lewis; Louise H Naylor; Ilkka Heinonen; Kathryn A Ellis; Ester Cerin; Philip N Ainslie; Daniel J Green
Journal:  J Appl Physiol (1985)       Date:  2019-02-07

2.  Investigation of the predictive validity of laser-EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers.

Authors:  Klaus Schaffler; Laurent B Nicolas; Andreas Borta; Tobias Brand; Peter Reitmeir; Robert Roebling; Joachim Scholpp
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

3.  Metabolic syndrome increases dietary α-tocopherol requirements as assessed using urinary and plasma vitamin E catabolites: a double-blind, crossover clinical trial.

Authors:  Maret G Traber; Eunice Mah; Scott W Leonard; Gerd Bobe; Richard S Bruno
Journal:  Am J Clin Nutr       Date:  2017-01-11       Impact factor: 7.045

4.  Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models.

Authors:  Peter Loudon; Pieter Siebenga; Donal Gorman; Katrina Gore; Pinky Dua; Guido van Amerongen; Justin L Hay; Geert Jan Groeneveld; Richard P Butt
Journal:  Br J Clin Pharmacol       Date:  2017-11-28       Impact factor: 4.335

5.  Effect of Using a Sit-Stand Desk on Ratings of Discomfort, Fatigue, and Sleepiness Across a Simulated Workday in Overweight and Obese Adults.

Authors:  Robert J Kowalsky; Sophy J Perdomo; John M Taormina; Christopher E Kline; Andrea L Hergenroeder; Jeffrey R Balzer; John M Jakicic; Bethany Barone Gibbs
Journal:  J Phys Act Health       Date:  2018-08-24

6.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

7.  Linear combinations come alive in crossover designs.

Authors:  Jonathan J Shuster
Journal:  Stat Med       Date:  2017-07-06       Impact factor: 2.373

8.  Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation.

Authors:  David J Goldberg; Benjamin French; Anita L Szwast; Michael G McBride; Bradley S Marino; Nicole Mirarchi; Brian D Hanna; Gil Wernovsky; Stephen M Paridon; Jack Rychik
Journal:  Pediatr Cardiol       Date:  2012-02-14       Impact factor: 1.655

9.  Concentration-QTc analysis with two or more correlated baselines.

Authors:  Yasushi Orihashi; Yuji Kumagai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-05-12       Impact factor: 2.745

10.  The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.

Authors:  Arne Ring; Tobias Brand; Sreeraj Macha; Kerstin Breithaupt-Groegler; Gudrun Simons; Beate Walter; Hans J Woerle; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2013-04-24       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.